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Abstract
Background Circulatory support during percutaneous
coronary intervention (PCI) in patients with ST-element
elevation myocardial infarction (STEMI) aims at main-
taining hemodynamic stability and organ perfusion.
However, continuous flow pumps may interfere with the
normal pulsatile circulation and the microcirculatory
function. Sidestream dark field (SDF) imaging allows the
visualization of microvascular structure and function of
tissue and may provide information regarding the efficacy
of the circulatory support.
Methods Sidestream dark field was used to study the
sublingual microcirculation (MC) in six anterior STEMI
patients treated with PCI; three patients received Impella
LP2.5 percutaneous left ventricular support (Impella group)
and three patients received no support (control group). MC
was assessed at baseline, at 24, 48 and 72 h after PCI. Data
were analyzed using a validated scoring method and the
microvascular flow index (MFI) and perfused vessel density
(PVD) were calculated. MC of three healthy controls was
used as normalized standard.
Results Normal MC depending on both functional capil-
lary density (PVD) and flow velocity or quality (MFI), as
observed in healthy controls, was only achieved in the
Impella group and paralleled improvement in LV function.
Functional capillary density in the control and Impella
groups were respectively equal and above the level of
healthy controls. The quality of microcirculatory flow only
in the Impella group reached values of healthy controls.
Conclusions Microcirculation assessed by SDF improved
in STEMI patients treated with the Impella LP2.5 to levels
observed in healthy persons and remained suboptimal after
72 h in patients without support. Sublingual SDF to assess
MC may serve as a monitor of effective myocardial
recovery after PCI and optimization of organ perfusion.
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Introduction
Reperfusion therapy for acute ST-elevation myocardial
infarction (STEMI) aims at early restoration of coronary
circulation [1, 2]. It reduces infarct size and improves
residual left ventricular (LV) function after STEMI.
Primary percutaneous coronary intervention (PCI) is the
choice of treatment for STEMI patients, especially when in
cardiogenic shock [3–5]. In STEMI patients with cardio-
genic shock, mechanical left ventricular support aims at
improving the circulatory conditions of both the coronary
arteries and other organs [6–9]. The circulatory response at
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microvascular level has been investigated in hemorrhagic
and septic shock models, including ischemia–reperfusion
injury [10–12]. In patients with heart failure and cardio-
genic shock, disturbances of the microcirculation (MC)
have also been described. However to date, little is known
about the alterations in tissue perfusion and circulatory
characteristics at the microvascular level, particularly in the
acute phase of STEMI. Additionally, the effect of circula-
tory support on MC in STEMI patients after PCI has not
been studied before [13–16]. Furthermore, the interference
of the continuous flow of a circulatory support device with
the normal vascular pulsatility is another unsolved issue.
We evaluated the microcirculatory response over time in
several conditions with a non-invasive imaging modality
called Sidestream dark-field (SDF, Microvision Medical,
Amsterdam, The Netherlands) [17–19]. We compared MC
between patients treated with and without LV circulatory
support by an axial flow pump in STEMI patients after
primary PCI. In concordance to the AMC MACH 2 study,
we hypothesized that improvement of myocardial function
and improved circulation with Impella support would have
a positive effect on the peripheral MC and therefore tissue
perfusion [20, 21].
Materials and methods
Patients and study design
The study was a sub-study of the non-randomized con-
trolled AMC MACH 2 study and has been approved by the
ethics committee of the Academic Medical Center
(Amsterdam, the Netherlands) [20, 22]. As described ear-
lier, we hypothesized that mechanical unloading of the left
ventricle in STEMI patients treated by PCI may give the
myocardium time to recuperate from ischemic stunning
and may reduce infarct size. This may be particularly true
in STEMI patients with cardiogenic shock or pre-shock,
who have a large ischemic area at risk for necrosis. Prior to
the initiation of a large trial in this patient category, as
prolonged mechanical cardiac support with the novel
Impella assist device was never evaluated in the setting of
STEMI before, the MACH 2 study was designed to assess
safety and feasibility of prolonged Impella support in a
group of less severely hemodynamically compromised
patients, which still might benefit from left ventricular
unloading (i.e. anterior STEMI).
Written informed consent was obtained from each
patient prior of inclusion. Patients between 30 and 80 years
of age, who presented with a first anterior STEMI within
6 h after onset of symptoms were eligible for enrolment.
Exclusion criteria were mainly deep cardiogenic shock,
mechanical ventilation, blood transfusion in the previous
24 h, known hemoglobin diseases such as sickle cell or
thallasemia, stroke or transient ischemic attack within the
previous 4 weeks as well as exclusion criteria related to the
ability to insert the Impella device such as: the presence of
a mural thrombus in the left ventricle and severe aortic
stenosis or the presence of a mechanical aortic valve. The
last three consecutive patients with (Impella group n = 10)
and the last three without circulatory support (non-support
control group n = 10) of the MACH 2 study were selected
for the MC sub-study. The Impella group patients had
circulatory support for 3 days with the Impella LP2.5
immediately after primary PCI. The control group received
routine care after primary PCI, including IABP therapy, as
deemed necessary by the attending operator in one patient.
Three healthy controls who matched for age and body mass
index provided microcirculatory control data.
Impella LP 2.5
As described earlier, the Impella LP2.5 is a novel catheter
(9 Fr) mounted micro-axial rotary blood pump (12 Fr),
designed for short-term mechanical circulatory support. It
is inserted through a femoral approach and positioned
across the aortic valve into the left ventricle. Expelling
aspirated blood from the left ventricle into the ascending
aorta, the Impella is able to provide flow up to 2.5 L/min.
Data collection and echocardiography
Procedural and laboratory data, clinical history and
admission medication were prospectively collected. Blood
samples were taken for determination of troponin T, creatine
kinase, creatine kinase-MB (CK-MB) and NT-proBNP
at admission, post-PCI and every 6 h during the first 72 h
of admission.
Global left ventricular ejection function (LVEF) in both
groups was determined on transthoracic echocardiography
(TTE) immediately after PCI (baseline) and at 3 days (after
Impella removal). Baseline TTE also served to assess the
presence of LV mural thrombus, which is an exclusion
criterion for Impella therapy. A standard imaging protocol
was used based on apical 4- and 2-chamber views. Analysis
were performed by an independent core lab (DCRI echo-
cardiography core laboratory, Duke University, Durham,
NC, USA) blinded to treatment assignment.
Microcirculatory measurements and analysis
Assessment of the sublingual MC was performed using
SDF, a hand-held microscope with light-emitting diodes
(LEDs) arranged in a ring formation at the tip of the probe.
These LEDs emit at a wavelength 550 ± 10 nm which is
absorbed by hemoglobin in erythrocytes, which are
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visualized as dark flowing cells in the microvascular net-
work consisting of small (0–20 lm), medium (21–50 lm)
and large (51 lm and larger) vessels. In the Impella group
baseline images of the MC are recorded after PCI but
before Impella support. Thereafter, microcirculatory
recordings are obtained immediately after start of support,
at 24, 48 h of support and after device removal at 72 h. In
the non-support control group microcirculatory assessment
is performed at corresponding time points. The SDF device
is gently placed on the sublingual region of the patients to
avoid pressure artifacts. Subsequently, three to five
sequences of steady images of various regions were
obtained and stored as avi formatted video clips.
Analysis of the microvascular network is carried out by
a validated scoring system described by De Backer et al.
[23]. For differentiation of the quality or type of flow in the
microvascular network the microvascular flow index (MFI)
is determined. This score is based on quantification of the
predominant type of flow per vessel type (small, medium,
large) in four equal quadrants of the obtained image. Flow
is characterized as absent (0), intermittent (1), sluggish (2),
or normal (3). The MFI score represents the averaged
values of the four quadrants [24].
In addition, the perfused vessel density (PVD), which is
an estimate of the functional capillary density, is calcu-
lated. The PVD is calculated by the percentage of the
vessel length of small vessels of all the vessels divided by
the analyzed image area. Tissue perfusion or oxygen
transport capacity by the MC is dependent on both func-
tional capillary density (reflected by PVD) and blood
velocity (reflected by MFI).
Statistical analysis
Data are presented as mean ± SD for continuous variables
and as frequencies for categorical variables. Differences
between the Impella group and control group in continuous
variables were tested with the Student’s t test. Comparisons
between baseline hemodynamic values, baseline LVEF,
MFI, PVD, and subsequent measurements were performed
in a paired fashion using the Student’s t test. All tests were
two tailed and a P value of \0.05 was considered statis-
tically significant. The statistical Package for the Social
Sciences (SPSS Inc., Chicago, IL, USA; version 15.0) was
used for statistical analysis.
Results
Patients
In total six consecutive patients from the MACH2 study
were included in this study. Microcirculatory observations
of three age and body mass index matched healthy controls
were used as normalized standard. All six anterior STEMI
patients were treated with primary PCI. After PCI,
three patients received Impella support (Impella group) and
three patients received routine care (non-support group).
The baseline clinical characteristics of the study population
are shown in Table 1. Patients of the Impella group had a
higher risk profile. At admission the Impella group had
higher serum levels of NT-proBNP, CK, CK-MB, peak
CK-MB, troponin T, as well as a higher area under the curve
of CK-MB and troponin T. In addition, baseline echocar-
diographic LVEF measurement, revealed a more depressed
mean ejection fraction in the Impella group compared to the
non-support group (i.e. 28 vs. 45%; P = 0.06). In overall,
the Impella assisted patients were in worse clinical condi-
tion at baseline compared with the control group.
Sublingual microvascular hemodynamics and LVEF
Adequate recordings were obtained at all times for all
patients. Figure 1a shows an example of the MC at baseline
in a patient from the Impella group. Figure 1b illustrates
the MC of the same patient 48 h later during Impella
support. In all patients visualization of the MC showed a
network of small, medium and large vessels. The MC was
assessed for MFI, representing the amount or quality of
flow in the microvascular bed, and the PVD, estimating the
functional capillary density. The MFI for both groups is
depicted in Fig. 2. In the Impella group, the MFI is sig-
nificantly more impaired at baseline compared to the non-
support control group; the MFI scores respectively were
1.8 ± 0.24 and 2.5 ± 0.11 (P \ 0.05). In other words, the
flow of small capillaries is more stagnant in the Impella
group at baseline. In the non-support control group no
significant changes in MFI are observed during the obser-
vation period and the MFI remains below values of healthy
controls. In contrast, in the Impella group an immediate
improvement of the MFI is observed after initiation
Impella support. The MFI increases from 1.8 ± 0.24 at
baseline to 1.97 ± 0.27 (P = NS) directly after start of the
Impella device, but does not become significant until after
24 h of assisted Impella support. This significant change in
MFI from 1.8 ± 0.24 at baseline to 2.5 ± 0.19 (P \ 0.05)
at 24 h of support was sustained even after removal of the
Impella at 72 h and remained significantly better than
the MFI of non-support controls. With Impella support the
quality of flow in the microvascular network did reach the
values observed in healthy controls. In contrast to the MFI,
the PVD was similar in both groups at baseline (Fig. 3).
However whereas the PVD remained equal in the non-
support control group, the PVD after 48 h was significantly
enhanced in the Impella group, even above values of
healthy controls. We found a significant increase of the
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PVD from 1.6 ± 0.1 to 1.9 ± 0.2 mm/mm2 (P \ 0.05) in
the Impella group after 48 h of assisted circulation, in
comparison to the controls where the PVD remained
respectively 1.6 ± 0.2 and 1.6 ± 0.3 mm/mm2 during the
same time course. The mean PVD value of the healthy
controls was 1.5 ± 0.2 mm/mm2.






Clinical characteristics and risk factors
Age (years) 53.6 ± 17.8 57.1 ± 11.7 0.79
Male gender (%) 2 (67) 3 (100) 0.273
Body mass index 25.3 ± 3.4 27.2 ± 6.1 0.665
Family history of cardiovascular disease (%) 1 (34) 1 (34)
Hypertension (%) 1 (34) 1 (34)
Diabetes (%) 0 0
Current smoker (%) 3 (100) 2 (67) 0.273
Hypercholesterolemia (%) 0 0
Stroke (%) 0 0
Previous myocardial infarction (%) 0 0
Previous coronary angioplasty (%) 0 0
Previous coronary artery bypass grafting (%) 0 0
Heart rate (bpm) 77.3 ± 22.9 80.3 ± 4.9 0.835
Diastolic pressure (mmHg) 79.0 ± 3.6 70.7 ± 5.0 0.08
Systolic pressure (mmHg) 126.0 ± 16.3 114.7 ± 5.7 0.321
Laboratory
Serum creatinine (lmol/L) 79.7 ± 27.2 62.7 ± 15.9 0.404
Hemoglobin (mmol/L) 9.2 ± 1.1 9.0 ± 0.5 0.86
Plasma glucose (mmol/L) 7.9 ± 0.6 7.1 ± 0.9 0.67
High sensitivity-CRP (mg/L) 75.6 ± 127.6 1.7 ± 2.2 0.373
NT-proBNP (ng/L) 4151.8 ± 6995.0 154.7 ± 103.2 0.78
CK-MB (lg/L) 105.3 ± 99.0 6.7 ± 5.9 0.16
Peak CK-MB (lg/L) 351.3 ± 124.7 242.1 ± 178.0 0.433
CK-MB AUC (lg h/L) 5629 ± 2625 4720 ± 3342 0.676
Troponin T AUC (lg h/L) 610 ± 219 165 ± 98 0.033
Angiographic characteristics
Ischemic time 6 h 50 min ± 4 h 28 min 3 h 12 min ± 1 h 10 min 0.244
LAD related infarction (%) 3 (100) 3 (100)
Multivessel disease (%) 2 (67) 0 0.083
TIMI 0 flow in culprit artery before intervention (%) 3 (100) 3 (100)
TIMI 3 flow in culprit artery after intervention (%) 3 (100) 3 (100)
Treatment related characteristics
Thrombosuction (%) 2 (67) 2 (67)
Number of stents 1 1
Stent length (mm) 19.7 ± 2.9 17.0 ± 1.7 0.242
IABP (%) 0 1 (33) 0.273
Reopro (%) 2 (67) 0 0.083
Echocardiographic parameters
LVEF at baseline 27.5 ± 3.5 44.6 ± 7.4 0.061
LVEF was measured immediately after primary PCI and in the Impella supported patients before Impella implantation
AUC Area under the curve, LAD left descending artery, TIMI thrombolysis in myocardial infarction, IABP intra aortic balloon pump, LVEF left
ventricular ejection fraction
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Hemodynamic and echocardiographic data
In the Impella group, LVEF improved from 28 ± 3% at
baseline immediately after PCI to 38 ± 3% (P \ 0.05)
after 3 days (after Impella removal), whereas in the control
group no significant improvement was observed. LVEF
changed from 45 ± 4 to 37 ± 7% (NS). Thus, the
improvement in MC in the Impella group paralleled the
functional improvement of LV function.
Discussion
This is the first study describing a positive relationship
between effective circulatory support and improvement in
sublingual MC, paralleling LV function improvement after
STEMI. Our data show that sublingual microcirculatory
flow is closely related to LV function improvement. It
would support the hypothesis that LV unloading and
circulatory support may improve LV function. This phe-
nomenon was demonstrated in STEMI patients with
percutaneous LVAD support after PCI [20]. Perhaps SDF
imaging of the sublingual microvascular bed may in a way
mirror the condition of the myocardium among other
parameters and it monitored the effect of adequate circu-
lation and tissue perfusion.
An intact and adequate functioning microvascular net-
work is essential for efficient tissue oxygenation, and
consequently, normal end-organ functioning. In our case
this also may have led to improved myocardial oxygena-
tion and LVEF. As expected, the worse clinical status of
the Impella group was reflected by a more impaired mi-
crocirculatory system. The observed microcirculatory
dysfunction in STEMI patients may be due to reduced
microcirculatory flow, despite seemingly sufficient circu-
lation, especially in the non-support group. Normal MC
depending on both the functional capillary density
(reflected by PVD) and flow velocity/quality (reflected by
MFI) as observed in healthy controls was only achieved in
STEMI patients when treated with Impella LP2.5 support.
The functional capillary density in both groups was at least
at the level of healthy controls, though in the Impella group
even above values of healthy controls. The latter may
reflect recruitment of microcirculatory vessels in the Im-
pella group. Moreover, the quality of microcirculatory flow
(MFI) only in the Impella group reached values of healthy
controls.
In other words, our STEMI patients receiving Impella
LP2.5 support experienced microcirculatory benefit. In
contrast, STEMI patients without support seemed hemo-
dynamically more stable and had better microcirculatory
conditions initially. However, in these patients MC did not
improve in the first few days, which may reflect sustained
microcirculatory distress. Their MC recovered over time
but never reached the normal level of healthy persons
during the observation period of 72 h. We may assume that
despite steady recovery, STEMI patients without circula-
tory support and impaired MC are exposed to an increased
risk of organ failure due to a priori suboptimal tissue
perfusion. It has been reported that microvascular deteri-
oration in septic patients, mainly expressed as decreased
vascular density, is associated with development of multi-
organ failure (MOF) [25, 26]. Besides microvascular
hypodensity, several mechanisms such as endothelial cell
dysfunction, altered vasomotor tone, reduction of red blood
cell deformability and leukocytes adhesions to endothelial
walls have a contributing role in progressive organ dys-
function [27, 28]. Furthermore, microcirculatory distress
appears to be an independent predictive factor for the
clinical outcome of patients in septic shock, and it has been
reported that it is of crucial importance that re-establish-
ment of the MC occurs within 24 h [28].
Fig. 1 a Microvascular network of a patient from the Impella group
at baseline (i.e. after PCI, before initiation of support). b MC of a
patient from the Impella group after 48 h of assisted circulation
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Remarkably, our study showed that restoration of the
microvascular system was already observed after 24 h of
circulatory support in hemodynamically compromised
patients, simultaneous to the correction of systemic hemo-
dynamics through the Impella LP2.5 assist device.
Moreover, not only did an increase in the microcirculatory
flow occur, but also this effect remained up to 72 h of
support and was even persistent after removal of the Impella
LP2.5. Another point of interest was the observation that the
appearance and rating of the MC among normal healthy
persons showed a very acceptable uniformity. Therefore,
the sublingually obtained MC observations in healthy per-
sons could be used as the normalized standard indeed.
Limitations
Our study has several limitations. First of all, there are
limitations to the method used to assess MC. One may
question whether the sublingual area is the representative
site to monitor MC in general or in specific organs such as
myocardial and renal tissue. It has been shown that
sublingual MC alterations in patients with severe heart
failure and sepsis were adequately related to outcome [28,
29]. Our study substantiates this observation in a different
population. Second, acquisition and analysis of the SDF
images are operator dependent. Despite a validating scoring
system, the selection and quality of the images determine
the quality of outcome. An important point of caution with
the SDF imaging is the pressure-induced microvascular
changes by application of the SDF microscope on tissue
surfaces. Also the number of patients studied is small. In the
recently initiated IMPRESS in STEMI trial comparing
IABP versus Impella LP2.5 in pre-shock STEMI patients,
MC assessment by means of SDF and its relationship with
LV recovery will be one of the secondary endpoints.
Conclusion
Microcirculation assessed by SDF improved in STEMI
patients treated with the Impella LP2.5 to levels observed
in healthy persons and remained suboptimal after 72 h in
Fig. 2 Microvascular flow index scores for individual patients (a)
and for the Impella group and non-support group (b). Time points
depicted are baseline, immediate after start of Impella support, at 24,
48 h of support and at 72 h after removal of the Impella device.
Asterisk in b denotes the mean MFI observed in healthy controls.
Dagger significant difference (P \ 0.05) between Impella group and
control group. Section symbol significant difference (P \ 0.05) of
value compared to baseline within Impella group
Fig. 3 Perfused vessel densities
(estimate of functional capillary
density) for individual patients
(a) and for the Impella group
and non-support group (b).
Asterisk in b denotes the mean
PVD observed in healthy
controls. Dagger significant
difference (P \ 0.05) between
Impella group and control
group. Section symbol
Significant difference
(P \ 0.05) of value compared to
baseline within Impella group
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patients without support. Sublingual SDF to assess MC
may serve as a monitor of effective myocardial recovery
after PCI and optimization of organ perfusion.
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